Tobias Klatte

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma
    Tobias Klatte
    Department of Urology, Otto von Guericke Universitat, Magdeburg, Germany
    BJU Int 100:209-14. 2007
  2. ncbi request reprint A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer
    Thomas Nelius
    Department of Urology, Otto von Guericke University Magdeburg, Leipziger Str 44, D 39120 Magdeburg, Germany
    BJU Int 98:580-5. 2006
  3. doi request reprint Pretreatment with interferon-alpha2a modulates perioperative immunodysfunction in patients with renal cell carcinoma
    Tobias Klatte
    Department of Urology, Otto von Guericke University, Magdeburg, Germany
    Onkologie 31:28-34. 2008
  4. doi request reprint Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies
    Arie S Belldegrun
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:2457-63. 2008
  5. pmc Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism
    Matthew B Rettig
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA
    Mol Cancer Ther 7:2662-71. 2008
  6. ncbi request reprint A novel resectoscope for transurethral resection of bladder tumors and the prostate
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, 10833 Le Conte Ave, Room B7 298A CHS, Los Angeles, California 90025 1738, USA
    J Urol 178:2331-6; discussion 2336. 2007
  7. ncbi request reprint Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer
    Thomas Nelius
    Department of Urology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    Onkologie 28:573-8. 2005
  8. doi request reprint Predictors of survival in patients with disease recurrence after radical nephroureterectomy
    Luis A Kluth
    Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA Department of Urology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    BJU Int 113:911-7. 2014
  9. ncbi request reprint Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Clin Cancer Res 13:7388-93. 2007
  10. ncbi request reprint Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA
    BJU Int 100:21-5. 2007

Detail Information

Publications29

  1. ncbi request reprint Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma
    Tobias Klatte
    Department of Urology, Otto von Guericke Universitat, Magdeburg, Germany
    BJU Int 100:209-14. 2007
    ....
  2. ncbi request reprint A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer
    Thomas Nelius
    Department of Urology, Otto von Guericke University Magdeburg, Leipziger Str 44, D 39120 Magdeburg, Germany
    BJU Int 98:580-5. 2006
    ....
  3. doi request reprint Pretreatment with interferon-alpha2a modulates perioperative immunodysfunction in patients with renal cell carcinoma
    Tobias Klatte
    Department of Urology, Otto von Guericke University, Magdeburg, Germany
    Onkologie 31:28-34. 2008
    ..Complex perioperative immunodysfunction occurs in patients with renal cell carcinoma undergoing surgery. Here, we report on the effect of preoperative treatment with interferon-alpha2a (IFN-alpha2a)...
  4. doi request reprint Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies
    Arie S Belldegrun
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:2457-63. 2008
    ..The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured...
  5. pmc Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism
    Matthew B Rettig
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA
    Mol Cancer Ther 7:2662-71. 2008
    ..Our study represents the first description of PE as a promising dietary agent for the prevention of the emergence of androgen independence that is driven in part by heightened NF-kappaB activity...
  6. ncbi request reprint A novel resectoscope for transurethral resection of bladder tumors and the prostate
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, 10833 Le Conte Ave, Room B7 298A CHS, Los Angeles, California 90025 1738, USA
    J Urol 178:2331-6; discussion 2336. 2007
    ..We performed a multicenter pilot and feasibility study of a novel working element for resectoscopes designed to improve the efficacy and safety of transurethral endoscopic surgery...
  7. ncbi request reprint Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer
    Thomas Nelius
    Department of Urology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    Onkologie 28:573-8. 2005
    ..We investigated the combination of docetaxel and estramustine in patients with HRPC regarding efficacy and prognostic parameters...
  8. doi request reprint Predictors of survival in patients with disease recurrence after radical nephroureterectomy
    Luis A Kluth
    Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA Department of Urology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    BJU Int 113:911-7. 2014
    ..To investigate whether clinical, pathological and/or biological factors at time of disease recurrence are also associated with cancer-specific outcomes in these patients...
  9. ncbi request reprint Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Clin Cancer Res 13:7388-93. 2007
    ..Here, we evaluated the significance of HIF-1 alpha in renal cell carcinoma (RCC)...
  10. ncbi request reprint Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA
    BJU Int 100:21-5. 2007
    ..To present a multicentre experience and the largest cohort to date of nonmetastatic (N0M0) synchronous bilateral renal cell carcinoma (RCC), as because it is rare the single-institutional experience is limited...
  11. doi request reprint Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance
    Brian Shuch
    Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:1324-31. 2008
    ..The objective of the current study was to investigate the outcomes of cytoreductive nephrectomy (CN) for patients who have an impaired performance status (ECOG PS 2/3)...
  12. ncbi request reprint The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 179:61-6. 2008
    ..To evaluate its role in the biology of clear cell renal cell carcinoma we performed a tissue microarray based study...
  13. doi request reprint Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90025 1738, USA
    J Urol 179:1719-26. 2008
    ..We characterized the clinicopathological features and the prognosis of small solid renal tumors defined as tumors 4 cm or smaller...
  14. ncbi request reprint Unclassified renal cell carcinoma: an analysis of 85 cases
    Pierre I Karakiewicz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    BJU Int 100:802-8. 2007
    ..To compare cancer-specific mortality in patients with unclassified renal cell carcinoma (URCC) vs clear cell RCC (CRCC) after nephrectomy, as URCC is a rare but very aggressive histological subtype...
  15. ncbi request reprint Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    BJU Int 99:821-4. 2007
    ....
  16. ncbi request reprint Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy
    Thomas Nelius
    Department of Urology, Texas Tech University Health Sciences Center, Medical Office Plaza, Suite 260, 3502 9th Street, Lubbock, TX 79415, USA
    Int Urol Nephrol 40:97-104. 2008
    ....
  17. ncbi request reprint Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience
    Tobias Klatte
    Department of Urology, University of California, Los Angeles, Los Angeles, California 90095 1738, USA, and Centre Hospitalier Universitaire Pontchaillou, Rennes, France
    J Urol 178:35-40; discussion 40. 2007
    ..We examined the current pT2 tumor classification of renal cell carcinoma and determined whether a tumor size cutoff exists that would improve prognostic accuracy...
  18. ncbi request reprint Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, California 90095 1738, USA
    Eur Urol 52:155-62. 2007
    ..To evaluate the prognostic role of tumour size in pathological stage T3a renal cell carcinoma (RCC) with fat invasion only and to assess whether this subgroup maintains its relevance over the other pathological stages...
  19. doi request reprint Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival
    Brian Shuch
    Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:1641-8. 2008
    ..The objective of the current study was to assist in the creation of treatment guidelines...
  20. doi request reprint Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma
    Allan J Pantuck
    J Clin Oncol 26:3105-7; author reply 3107-9. 2008
  21. doi request reprint Surveillance for renal cell carcinoma: why and how? When and how often?
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
    Urol Oncol 26:550-4. 2008
    ..The current surveillance protocol at our institution is based on the UISS. It is expected that molecular markers such as p53 will allow more individualized surveillance strategies in the future...
  22. pmc Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma
    Jean Jacques Patard
    CNRS UMR6061 Genetics and development, IFR 140, University of Rennes 1, Rennes, France
    Int J Cancer 123:395-400. 2008
    ....
  23. ncbi request reprint Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA
    J Urol 177:2081-6; discussion 2086-7. 2007
    ..We evaluated the prognosis, risk factors and relevance of the primary-free interval in a large cohort with metachronous bilateral renal cell carcinoma...
  24. ncbi request reprint Update on partial nephrectomy and novel techniques
    Stephen B Riggs
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Urol Oncol 25:520-2. 2007
    ..With either approach, the chance for renal preservation would appear to be a major benefit while "non-hilar" clamping techniques during the open approach may maximize the likelihood for maintenance of long-term renal function...
  25. ncbi request reprint Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Cancer 109:2257-67. 2007
    ..The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway in renal cell carcinoma (RCC)...
  26. ncbi request reprint Metastatic melanoma to the kidney presenting with renal vein tumor thrombus
    Tobias Klatte
    Department of Urology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1738, USA
    Urology 69:982.e7-9. 2007
    ..The patient later had tumor recurrence at multiple sites. He did not respond to systemic treatment and died 5 months later...
  27. ncbi request reprint Prognostic factors for renal cell carcinoma with tumor thrombus extension
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 178:1189-95; discussion 1195. 2007
    ..We identified prognostic factors for renal cell carcinoma with tumor thrombus extension and assessed whether the current T3 classification could be improved...
  28. ncbi request reprint Differential diagnosis of hypercalcemia in renal malignancy
    Tobias Klatte
    Department of Urology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1738, USA
    Urology 70:179.e7-8. 2007
    ..The differential diagnosis of hypercalcemia in renal malignancy is presented...
  29. ncbi request reprint Prognostic factors and selection for clinical studies of patients with kidney cancer
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, United States
    Crit Rev Oncol Hematol 65:235-62. 2008
    ..This review will examine the current staging modalities and prognostic factors associated with RCC as well as the selection of patients most likely to benefit from clinical trials...